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common treatment related grade 3-4 AEs (n=13) were: thrombocytope-
nia (54%) and neutropenia (46%), with no treatment-related deaths. Of 
16 pts withdrawn, 11 had progression and 5 had chemotherapy delay or 
AEs. 5/7 pts with NSCLC completed 6 cycles and 4 are alive at 11.5-14 
months. One NSCLC patient had an investigator-conﬁrmed partial 
response before progression with brain metastases after 15 cycles. 
Conclusions: The IMO-2055-chemotherapy combination showed signs 
of efﬁcacy in moderately pretreated NSCLC patients. All DLTs in this 
study were hematological and could be attributed to the chemotherapy 
alone, as indicated in a previous report of gemcitabine-carboplatin in 
ﬁrst line pts (34% grade 3/4 neutropenia and 28% grade 3/4 thrombo-
cytopenia) (Zatloukal P et al, ASCO 2002). The absence of hemato-
logical DLTs in the IMO-2055 8mg d9, 16 schedule is encouraging. 
Recruitment continues for the IMO-2055 12mg d9, 16 schedule. IMO-
2055 warrants consideration for additional study in NSCLC.
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Background: The standard treatment for patients with unresectable 
or locally advanced NSCLC is radiotherapy. Erlotinib (Tarceva®) is 
an oral EGFR TKI, that has shown activity in recurrent and metastatic 
NSCLC. This phase II study aims to assess and compare the toxicity 
and activity of the addition to Erlotinib to radiotherapy.
Methods: Patients with stage IA-IIIB medically inoperable or unresect-
able NSCLC, good performance status, measurable disease by RECIST 
criteria, and written informed consent were enrrolled into this prospec-
tive randomized phase II study. Arm A consisted in thoracic 3D radio-
therapy (66Gy in 33 fractions during 6 weeks). Arm B was Erlotinib 
150 mg po qd starting and given concurrently with 3D radiotherapy 
(66Gy in 33 fractions during 6 weeks). Treatment with Erlotinib was 
maintained for 6 months.
Results: A total of 17 pts have been randomized from March 2006 to 
the moment of this analysis.
Complete data for 13 pats are available (8 Arm A, 5 Arm B). All pts 
were caucasian men. Pretreatment characteristics, including age, ECOG 
PS, smoking habits, histological features, and stage were similar
The incidence of acute esophagitis and other radiotherapy related tox-
icities was similar in the two arms of treatment. Detailed information 
about skin toxicity is available for three patienes with 2 patients having 
dermatitis in the radiation area (one arm A one arm B) and one patient 
with an exanthema out of the radiation area (arm B) probably related to 
Erlotinib.
No dose reductions of Erlotinib were necessary. 
Conclusions: The addition of Erlotinib to radiotherapy in the treatment 
of this patients population is feasible and does not appear to increase 
in-ﬁeld toxicities. Data on survival will be presented. Study is ongoing
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Background: The EGFR TK inhibitor erlotinib is approved for the 
treatment of patients with non-small cell lung cancer (NSCLC) as a sin-
gle agent in 2nd and 3rd line treatment. We present data of a prospec-
tive study, which includes unselected chemotherapy-naïve patients not 
suitable for ﬁrst line conventional chemotherapy treated with erlotinib. 
Methods: Eligibility criteria included stage IIIB-IV, conﬁrmed disease, 
PS≤2, age≥18, adequate organ function, and written informed con-
sent. Unselected chemonaïve patients were included for this analysis. 
Erlotinib was administered at a dose of 150 mg/day orally until disease 
progression or withdrawal. Primary objective was to determine time 
to progression. The large subgroup of patients treated as ﬁrst line was 
analyzed to determine the efﬁcacy and safety of erlotinib in this popu-
lation.
Results: 443 patients were included in this subanalysis. Median age 
was 72 years (range (26–90). 59% of the patients were male and 41% 
female and 99% of them were caucasian. Histologies were: adenocar-
cinoma 64%, squamous 16%, large cell 13%, others 7%. Patients who 
had stage IIIB were 24% and 76% had stage IV. Their performance 
status was: PS 0, 19%, PS 1, 51% and PS 2, 30%. Regarding their 
smoking history, 63% of the patients had smoked or are currently 
smokers. 248 patients were evaluable for response, and 6 of them had 
CP, 72 PR and 91 SD. The Response Rate was 31.45% and the Clinical 
Beneﬁt (CR+PR+SD) was 70%. Response Rate was higher in females 
(49.5%, p<0.0001) and in never smokers (16.5% p<0.0001). Median 
time to progression was 6.6 months (95% CI 5.2–8.6).In this population 
the median survival time was 7.1 months (95% CI 6.1–8.4). Regarding 
the safety proﬁle of erlotinib in this population, the main toxicities were 
rash and diarrhea, resulting up to 9% of the patients with grade 3 or 4 
rash, and 2 patients with grade 4 diarrhea. In the multivariate analysis, 
smoking history was the most signiﬁcant predictive factor for TTP and 
survival. 
Conclusions: This result conﬁrms that erlotinib is active when used 
as single agent in ﬁrst line patients with NSCLC in patients that are 
not suitable for chemotherapy. Smoking history is the most signiﬁcant 
predictive factor for TTP and survival. Further studies in this popula-
tion are warranted.
